Prosecution Insights
Last updated: August 06, 2026

Cermak & Mcgowan LLP

32 pending office actions • 19 clients • 30 examiners • 20 art units • 0 of 32 (0%) have an AI response strategy ready

Quality Metrics (n=2645 apps, methodology: how we score firms)

82.9%
Allowance Rate
n=2645
+0.69σ
Allowance Rate (norm)
n=2645
3.8
OAs to Allowance
n=1823
+0.09σ
OAs to Allow (norm)
n=1823
1201 days
Time to Allowance
n=1823
+10.3pp
Interview Lift
n=2645
25.7%
RCE Rate
n=2645
3.8%
Appeal Rate
n=2645

Rejection Performance (% of received rejections ultimately overcome)

73.8%
§101 Overcome
n=141
79.3%
§102 Overcome
n=836
81.4%
§103 Overcome
n=1288
83.1%
§112 Overcome
n=1208

Specialization & Scale

C12P, C12N, A61K
Top CPC Subclasses
18%
Top-3 CPC Share
n=2645
1
Practitioners
n=2645
2645.0
Apps / Practitioner
n=2645

Portfolio Summary

32
Total Pending OAs
23
Non-Final OAs
7
Final Rejections
2
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 15 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

12
Overdue
1
Due this week
1
Due this month
0
Due in next 60 days
1
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 15 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (12)Due ≤ 7 days (1)Due ≤ 30 days (1)Due later (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

17
Hard (53%)
13
Medium (41%)
2
Easy (6%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 + other3 (9%)
§103 only6 (19%)
§102 only1 (3%)
§112 only2 (6%)
Double-patenting + other6 (19%)
Multi-statute (no §101)14 (44%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

26
Life Sciences
81% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
1
Mechanical / Eng
3% of docket
5
Business / Other
16% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

320 h
Manual time on pending OAs
64 h
Time saved (low, 20%)
112 h
Time saved (mid, 35%)
2.8 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
WEBB, WALTER E 2 46.5% +18.6%
MARTIN, KEVIN STEPHEN 2 75.7% +24.4%
MOAZZAMI, NAGHMEH NINA 1 73.1% +41.9%
BEHARRY, ZANNA MARIA 1 23.2% +52.7%
STEINKE, SEAN JAMES 1 12.5% +42.9%
STRANSKY, KATRINA MARIE 1 74.1% +24.5%
HOFFMAN, SUSAN COE 1 54.2% +25.5%
BARRON, SEAN C 1 53.3% +30.6%
BLANCHETTE, JOSHUA B 1 47.6% +31.0%
SCOTLAND, REBECCA LYNN 1 0.0% +0.0%

Hard Cases (18)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
18502426 ELECTRICAL CONDITION DATA MANAGEMENT APPARATUS, PROGRAM, AND METHOD BLANCHETTE, JOSHUA B 91d overdue
17799466 A PROCESS FOR THE PRODUCTION OF A BAKED PRODUCT WITHOUT ADDITION OF SUGAR TRAN, LIEN THUY 73d overdue
18155281 METHODS OF EXTENDING LIFESPAN BY ADMINISTERING FERROPTOSIS INHIBITORS MARTIN, KEVIN STEPHEN 31d overdue
17999081 Use of SAA, rSAA or inhibitors of SAA in the treatment of dysregulated inflammation JUEDES, AMY E 17d overdue
18250643 Anti-Microbial Skin-Care Composition Comprising Beta-Glucan and Natural Oil WEBB, WALTER E 15d overdue
18354129 COSMETIC COMPOSITION SCOTLAND, REBECCA LYNN 4d overdue
18836116 Method for Inducing Differentiation from Pluripotent Stem Cell to Epidermal Keratinocyte BEHARRY, ZANNA MARIA
18705154 A Three-Dimensional Scaffold for Medical Use Comprising Animal Collagen STEINKE, SEAN JAMES

Interview Candidates (11)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
18502426 ELECTRICAL CONDITION DATA MANAGEMENT APPARATUS, PROGRAM, AND METHOD BLANCHETTE, JOSHUA B 91d overdue
18155281 METHODS OF EXTENDING LIFESPAN BY ADMINISTERING FERROPTOSIS INHIBITORS MARTIN, KEVIN STEPHEN 31d overdue
17438158 Heteroaromatic and Heterobicyclic Aromatic Derivatives for the Treatment of Ferroptosis-Related Disorders MARTIN, KEVIN STEPHEN 31d overdue
17939570 Liquid Composition for Cleaning, Sanitizing and/or Disinfecting WEBB, WALTER E 26d overdue
18250643 Anti-Microbial Skin-Care Composition Comprising Beta-Glucan and Natural Oil WEBB, WALTER E 15d overdue
18904277 Method for Preparing a Three-Dimensional Scaffold for Medical Use MOAZZAMI, NAGHMEH NINA
18836116 Method for Inducing Differentiation from Pluripotent Stem Cell to Epidermal Keratinocyte BEHARRY, ZANNA MARIA
18705154 A Three-Dimensional Scaffold for Medical Use Comprising Animal Collagen STEINKE, SEAN JAMES

Client Portfolio (19 clients)

Top Art Units

Art UnitApps
16552
16532
16122
16242
17932
16512
16572
16191
36841
16151

Pending Office Actions

App #TitleClientExaminerArt UnitStatutesStatusDue inAIFiled
18904277 Method for Preparing a Three-Dimensional Scaffold for Medical Use Askel Heathcare Ltd. MOAZZAMI, NAGHMEH NINA §103DP Non-Final OA Pending Oct 02, 2024
18836116 Method for Inducing Differentiation from Pluripotent Stem Cell to Epidermal Keratinocyte The Jikei University BEHARRY, ZANNA MARIA §102§112 Non-Final OA Pending Aug 06, 2024
18705154 A Three-Dimensional Scaffold for Medical Use Comprising Animal Collagen Askel Healthcare Ltd. STEINKE, SEAN JAMES 1619 §102§103§112Other Non-Final OA Pending Apr 26, 2024
18705215 A PLA-COLLAGEN SCAFFOLD FOR MEDICAL USE LOADED WITH CELLS Askel Healthcare Ltd. STRANSKY, KATRINA MARIE §102§103§112DP Non-Final OA Pending Apr 26, 2024
18702300 Composition for Promoting the Assimilation of an Oligosaccharide Morinaga Milk Industry Co., Ltd. HOFFMAN, SUSAN COE 1655 §101§102§103§112 Non-Final OA Pending Apr 17, 2024
18631361 BACTERIUM MODIFIED TO EXPRESS HETEROLOGOUS Tat PROTEIN Ajinomoto Co., Inc. BARRON, SEAN C §102§103 Non-Final OA Pending Apr 10, 2024
18502426 ELECTRICAL CONDITION DATA MANAGEMENT APPARATUS, PROGRAM, AND METHOD Ajinomoto Co., Inc. BLANCHETTE, JOSHUA B 3684 §101§103 Non-Final OA 91d overdue Pending Nov 06, 2023
18354129 COSMETIC COMPOSITION Ajinomoto Co., Inc. SCOTLAND, REBECCA LYNN 1615 §103 Final Rejection 4d overdue Pending Jul 18, 2023
18354140 COSMETIC COMPOSITION Ajinomoto Co., Inc. SAEED, ALI S 1616 §103 Non-Final OA Pending Jul 18, 2023
18351225 METHOD FOR PRODUCING PHYTOSPHINGOSINE OR PHYTOCERAMIDE Evolva SA MEAH, MOHAMMAD Y 1652 §102§103§112DP Non-Final OA Pending Jul 12, 2023
18350982 METHOD FOR PRODUCING PHYTOSPHINGOSINE OR PHYTOCERAMIDE Danstar Ferment AG KOROTCHKINA, LIOUBOV G 1653 §103§112DP Non-Final OA 49d overdue Pending Jul 12, 2023
18270073 JUDGMENT SUPPORTING INFORMATION GENERATING METHOD, JUDGMENT SUPPORTING INFORMATION GENERATING SYSTEM, AND INFORMATION PROCESSING DEVICE Mcbi Inc. FUELLING, MICHAEL §101§103§112 Non-Final OA Pending Jun 28, 2023
18338927 SOLID CATALYST COMPOSITION FOR ORGANIC WASTE TREATMENT, MANUFACTURING METHOD THEREOF AND USE THEREOF Tetanti Agribiotech Inc. MCCLAIN, STARFARI TESHAWN 1736 §103 Non-Final OA 84d Pending Jun 21, 2023
18256080 Prebiotic Composition for Butyric Acid Bacteria Morinaga Milk Industry Co., Ltd. GALSTER, SAMUEL LEONARD 1693 §102 Final Rejection 70d overdue Pending Jun 06, 2023
18250643 Anti-Microbial Skin-Care Composition Comprising Beta-Glucan and Natural Oil Lantmännen Oats AB WEBB, WALTER E 1612 §103§112 Final Rejection 15d overdue Pending Apr 26, 2023
18246797 Use of Antcin H and Its Derivatives for Treating Central Nervous System Diseases Alps Biotech Co., Ltd. LEE, WILLIAM Y 1623 §103§112 Non-Final OA Pending Mar 27, 2023
18170671 PHARMACEUTICAL COMPOSITION COMPRISING MODIFIED NATURAL KILLER CELLS AND ANTIGEN-SPECIFIC T CELLS, MANUFACTURING METHOD THEREOF, AND METHOD OF USING THE SAME National Yang Ming Chiao Tung University GRABER, JAMES J 1631 §102§112DP Final Rejection 12d Pending Feb 17, 2023
18155281 METHODS OF EXTENDING LIFESPAN BY ADMINISTERING FERROPTOSIS INHIBITORS Collaborative Medicinal Development, LLC MARTIN, KEVIN STEPHEN 1624 §102§112 Non-Final OA 31d overdue Pending Jan 17, 2023
18152377 Novel Asphalt Binder Additive Compositions and Methods of Use Collaborative Aggregates, LLC MERKLING, SALLY ANNE 1738 §102§103 Non-Final OA Pending Jan 10, 2023
17999081 Use of SAA, rSAA or inhibitors of SAA in the treatment of dysregulated inflammation Lika Antisepsis Gbr JUEDES, AMY E 1644 §103§112 Final Rejection 17d overdue Pending Nov 17, 2022
18048519 Method For Producing Soy Sauce-Like Seasoning Ajinomoto Co., Inc. MCCLAIN, TYNESHA L. 1793 §102§103§112 Non-Final OA Pending Oct 21, 2022
17910175 A Consumable Product Comprising Malted Cereals for Promoting Recovery at Physical Activity LANTMÄNNEN FUNCTIONAL FOODS AB FIEBIG, RUSSELL G 1655 §103 Non-Final OA 35d overdue Pending Sep 08, 2022
17939570 Liquid Composition for Cleaning, Sanitizing and/or Disinfecting Corticalis AS WEBB, WALTER E 1612 §103 Final Rejection 26d overdue Pending Sep 07, 2022
17799466 A PROCESS FOR THE PRODUCTION OF A BAKED PRODUCT WITHOUT ADDITION OF SUGAR Lantmännen Unibake Holding A/S TRAN, LIEN THUY 1793 §103§112 Non-Final OA 73d overdue Pending Aug 12, 2022
17831877 METHOD FOR PRODUCING PEPTIDE HAVING PHYSIOLOGICAL ACTIVITY, AND PEPTIDE COMPRISING SHORT LINKER Ajinomoto Co., Inc. MONSHIPOURI, MARYAM 1651 §103§112 Non-Final OA Pending Jun 03, 2022
17714537 Modified Phenylalanine Dehydrogenase Ajinomoto Co., Inc. ZINGARELLI, SANDRA 1653 §112 Non-Final OA 232d overdue Pending Apr 06, 2022
17688035 COMPOSITION, PRODUCTION METHOD FOR PRODUCING THE SAME, AND METHOD OF PREVENTING CAKING Morinaga Milk Industry Co., Ltd. CURRENS, GRANT CARSON 1651 §103§112 Non-Final OA Pending Mar 07, 2022
17563532 METHOD OF TREATING GLIOBLASTOMA Lantmännen As-Faktor AB FISCHER, JOSEPH 1658 §103§112DP Non-Final OA Pending Dec 28, 2021
17611312 COMPOSITION Morinaga Milk Industry Co., Ltd. EDWARDS, JESSICA FAYE 1657 §103 Non-Final OA 5d Pending Nov 15, 2021
17480792 METHOD FOR PRODUCING ALLOLACTOSE Ajinomoto Co., Inc. BREEN, KIMBERLY CATHERINE 1657 §103§112 Non-Final OA Pending Sep 21, 2021
17438158 Heteroaromatic and Heterobicyclic Aromatic Derivatives for the Treatment of Ferroptosis-Related Disorders Collaborative Medicinal Development, LLC MARTIN, KEVIN STEPHEN 1624 §112Other Non-Final OA 31d overdue Pending Sep 10, 2021
17193092 Consumable Product Comprising Malted Dehulled Oats LANTMÄNNEN FUNCTIONAL FOODS AB KIM, BRYAN 1792 §103§112 Final Rejection Pending Mar 05, 2021

Managing Cermak & Mcgowan LLP's Patent Prosecution?

IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month